This is an index of side effect / adverse reaction reports (a.k.a. adverse event reports) related to Zevalin (Ibritumomab Tiuxetan) and submitted to the FDA during the sample period of about a year. The information is not vetted and should not be considered as verified clinical evidence.
Reports by Event Outcome
All Cases (58)
Death (21)
Life Threatening Events (1)
Disability (2)
Reports by Reaction Type
White Blood Cell Count Decreased (11),
Platelet Count Decreased (11),
Myelodysplastic Syndrome (9),
Sepsis (8),
Neutrophil Count Decreased (7),
Anaemia (6),
Febrile Neutropenia (6),
Neoplasm Malignant (6),
Herpes Zoster (5),
Pancytopenia (5),
Diarrhoea (5),
Jaundice (4)
Below are a few examples of reports where side effects / adverse reactions may be related to Zevalin (Ibritumomab Tiuxetan). For a complete list or a specific selection of reports, please use the links above.
Possible Zevalin side effects in
Reported by a consumer/non-health professional from Germany on 2012-08-15
Patient:
Reactions: Haemorrhagic Stroke, Thrombocytopenia
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Rituximab
Dosage: unk, single
Indication: Mantle Cell Lymphoma Recurrent
Start date: 2005-07-29
End date: 2005-07-29
Rituximab
Dosage: unk, single
Start date: 2005-07-01
End date: 2005-07-01
Zevalin
Dosage: 0.3 mci/kg, single
Indication: Mantle Cell Lymphoma Recurrent
Start date: 2005-07-29
End date: 2005-07-29
Other drugs received by patient: Fludara
Possible Zevalin side effects in
Reported by a physician from United States on 2012-08-09
Patient:
Reactions: Encephalopathy
Adverse event resulted in: death
Drug(s) suspected as cause:
Zevalin
Dosage: unk
Indication: Product Used FOR Unknown Indication
Hematopoetic Progenitor Cells Human
Dosage: unk
Indication: Product Used FOR Unknown Indication
Multi-Agent Chemotherapy
Dosage: unk
Indication: Product Used FOR Unknown Indication
Possible Zevalin side effects in 60 year old male
Reported by a health professional (non-physician/pharmacist) from United States on 2012-08-07
Patient: 60 year old male, weighing 107.0 kg (235.4 pounds)
Reactions: Myoclonus
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Zevalin
Dosage: 30.4 mci/x 1/iv
Indication: Multiple Myeloma
Start date: 2012-06-06
Zevalin
Dosage: 5.493 micocuries/x 1/iv
Indication: Multiple Myeloma
Start date: 2012-05-30
Other drugs received by patient: Potassium Phosphates; Melphalan Hydrochloride; Gabapentin; Crestor; Aspirin; Dexamethasone; Metoprolol Tartrate; Ondansetron; Acid Prestudy; K-Phos Premix; Isosorbide; Levothyroxine Sodium; MAG Sulfur; Nifedipine; Lasix; Protonix; Nahco3
Possible Zevalin side effects in male
Reported by a health professional (non-physician/pharmacist) from Italy on 2012-07-30
Patient: male
Reactions: Myelodysplastic Syndrome, Azotaemia
Adverse event resulted in: death
Drug(s) suspected as cause:
Doxorubicin Hydrochloride
Dosage: 380 mg
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2007-03-13
End date: 2007-05-17
Zevalin
Dosage: 1.6 mg
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2007-07-19
End date: 2007-07-19
Vincristine
Dosage: 8 mg
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2007-03-13
End date: 2007-05-17
Cyclophosphamide
Dosage: 5700 mg
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2007-03-13
End date: 2007-05-17
Possible Zevalin side effects in 76 year old male
Reported by a physician from Italy on 2012-07-30
Patient: 76 year old male
Reactions: Neoplasm Malignant, Myelodysplastic Syndrome
Adverse event resulted in: death
Drug(s) suspected as cause:
Doxorubicin HCL
Dosage: 380 mg, cyclic
Indication: B-Cell Lymphoma
Start date: 2007-03-13
End date: 2007-05-17
Vincristine Sulfate
Dosage: 8 mg, cyclic
Indication: B-Cell Lymphoma
Start date: 2007-03-13
End date: 2007-05-17
Cyclophosphamide
Dosage: 5700 mg, cyclic
Indication: B-Cell Lymphoma
Start date: 2007-03-13
End date: 2007-05-17
Zevalin
Dosage: 1.6 mg, total
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2007-07-19
End date: 2007-07-19
Possible Zevalin side effects in
Reported by a consumer/non-health professional from Germany on 2012-07-13
Patient:
Reactions: White Blood Cell Count Decreased, Pancreatic Carcinoma, Platelet Count Decreased, Neutrophil Count Decreased
Adverse event resulted in: death
Drug(s) suspected as cause:
Zevalin
Dosage: unk, single
Indication: Lymphoma
Start date: 2010-12-14
End date: 2010-12-14
Zevalin
Dosage: unk, single
Start date: 2010-12-07
End date: 2010-12-07
Possible Zevalin side effects in male
Reported by a health professional (non-physician/pharmacist) from United States on 2012-07-10
Patient: male, weighing 48.5 kg (106.8 pounds)
Reactions: Myoclonus
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Zevalin
Dosage: 30.4 mci, single
Indication: Multiple Myeloma
Start date: 2012-06-06
End date: 2012-06-06
Zevalin
Dosage: 5.493 mci, single
Start date: 2012-05-30
End date: 2012-05-30
Rituxan
Dosage: 220 mg, single
Indication: Multiple Myeloma
Start date: 2012-06-06
End date: 2012-06-06
Rituxan
Dosage: 220 mg, single
Start date: 2012-05-30
End date: 2012-05-30
Other drugs received by patient: Folic Acid; Dexamethasone; Metoprolol; K-Phos Premix; Lasix; Magnesium Sulfate; Sodium Bicarbonate; Aspirin; Gabapentin; Nifedipine; Crestor; Ondansetron; Protonix; Melphalan Hydrochloride; Isosorbide Mononitrate; K-Phos Neutral; Levothyroxine Sodium
Possible Zevalin side effects in
Reported by a consumer/non-health professional from Germany on 2012-06-21
Patient:
Reactions: Sepsis, Progressive Multifocal Leukoencephalopathy, Meningitis Tuberculous
Adverse event resulted in: death
Drug(s) suspected as cause:
Cisplatin
Dosage: unk
Indication: Product Used FOR Unknown Indication
Neupogen
Dosage: unk
Indication: Product Used FOR Unknown Indication
Rituxan
Dosage: unk
Indication: Product Used FOR Unknown Indication
Cyclophosphamide
Dosage: 2000 mg/m2, unk
Indication: Product Used FOR Unknown Indication
Carboplatin
Dosage: unk
Indication: Product Used FOR Unknown Indication
Etoposide
Dosage: unk
Indication: Product Used FOR Unknown Indication
Zevalin
Dosage: unk
Indication: Product Used FOR Unknown Indication
Prednisone TAB
Dosage: unk
Indication: Product Used FOR Unknown Indication
Busulfan
Dosage: 12 mg/kg, unk
Indication: Product Used FOR Unknown Indication
Fludara
Dosage: 250 mg/m2, unk
Indication: Product Used FOR Unknown Indication
Doxorubicin Hydrochloride
Dosage: unk
Indication: Product Used FOR Unknown Indication
Ifosfamide
Dosage: unk
Indication: Product Used FOR Unknown Indication
Vincristine Sulfate
Dosage: unk
Indication: Product Used FOR Unknown Indication
Possible Zevalin side effects in
Reported by a consumer/non-health professional from Germany on 2012-06-14
Patient:
Reactions: Cervix Carcinoma Stage I, Platelet Count Decreased, Pyrexia, Neutrophil Count Decreased
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Zevalin
Dosage: 130 mbq, single
Start date: 2009-11-17
End date: 2009-11-17
Rituxan
Dosage: 400 mg, single
Start date: 2009-11-17
End date: 2009-11-17
Rituxan
Dosage: 400 mg, single
Indication: Follicle Centre Lymphoma, Follicular Grade I, II, III Stage I
Start date: 2009-11-24
End date: 2009-11-24
Zevalin
Dosage: 898 mbq, single
Indication: Follicle Centre Lymphoma, Follicular Grade I, II, III Stage I
Start date: 2009-11-24
End date: 2009-11-24
Other drugs received by patient: Isodine; Pyrinazin; Levofloxacin; PL Gran.; BIO Three / 01068501 /; Amlodipine; Restamin; Pursennid / 00571901 /; SP / 00312001 /
Possible Zevalin side effects in
Reported by a consumer/non-health professional from Canada on 2012-06-13
Patient:
Reactions: Sepsis, Progressive Multifocal Leukoencephalopathy, Meningitis Tuberculous
Adverse event resulted in: death
Drug(s) suspected as cause:
Neupogen
Dosage: unk
Indication: Product Used FOR Unknown Indication
Rituxan
Dosage: unk
Indication: Product Used FOR Unknown Indication
Busulfan
Dosage: 12 mg/kg, qd
Indication: Product Used FOR Unknown Indication
Cisplatin
Dosage: unk
Indication: Product Used FOR Unknown Indication
Cyclophosphamide
Dosage: 2000 mg/m2, qd
Indication: Product Used FOR Unknown Indication
Etoposide
Dosage: unk
Indication: Product Used FOR Unknown Indication
Ifosfamide
Dosage: unk
Indication: Product Used FOR Unknown Indication
Zevalin
Dosage: unk
Indication: Product Used FOR Unknown Indication
Prednisone TAB
Dosage: unk
Indication: Product Used FOR Unknown Indication
Vincristine Sulfate
Dosage: unk
Indication: Product Used FOR Unknown Indication
Fludara
Dosage: 250 mg/m2, qd
Indication: Product Used FOR Unknown Indication
Doxorubicin Hydrochloride
Dosage: unk
Indication: Product Used FOR Unknown Indication
Carboplatin
Dosage: unk
Indication: Product Used FOR Unknown Indication
Possible Zevalin side effects in
Reported by a consumer/non-health professional from Germany on 2012-06-01
Patient:
Reactions: Cardiomyopathy
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Zevalin
Other drugs received by patient: Crestor
Possible Zevalin side effects in 36 year old female
Reported by a physician from Korea, Republic of on 2012-05-24
Patient: 36 year old female
Reactions: Multi-Organ Failure, Interstitial Lung Disease, Acute Respiratory Distress Syndrome
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Zevalin
Dosage: 0.4 mci/kg
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2005-10-01
End date: 2005-10-01
Rituximab
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2005-10-01
End date: 2005-10-01
Possible Zevalin side effects in
Reported by a physician from Germany on 2012-05-18
Patient:
Reactions: Prostate Cancer
Drug(s) suspected as cause:
Zevalin
Dosage: unk
Indication: Product Used FOR Unknown Indication
Start date: 2004-01-01
End date: 2004-01-01
Oncovin
Dosage: unk
Indication: Product Used FOR Unknown Indication
Corticosteroid NOS
Dosage: unk
Indication: Product Used FOR Unknown Indication
Nitrogen Mustard
Dosage: unk
Indication: Product Used FOR Unknown Indication
Possible Zevalin side effects in
Reported by a consumer/non-health professional from Germany on 2012-05-18
Patient:
Reactions: Squamous Cell Carcinoma of Skin
Drug(s) suspected as cause:
Anthracycline
Dosage: unk
Indication: Product Used FOR Unknown Indication
Nitrogen Mustard
Dosage: unk
Indication: Product Used FOR Unknown Indication
Zevalin
Dosage: unk
Indication: Product Used FOR Unknown Indication
Start date: 2004-01-01
End date: 2004-01-01
Corticosteroid NOS
Dosage: unk
Indication: Product Used FOR Unknown Indication
Oncovin
Dosage: unk
Indication: Product Used FOR Unknown Indication
Possible Zevalin side effects in
Reported by a consumer/non-health professional from Germany on 2012-05-16
Patient:
Reactions: Ventricular Hypokinesia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Zevalin
Possible Zevalin side effects in male
Reported by a consumer/non-health professional from United States on 2012-05-04
Patient: male, weighing 104.3 kg (229.5 pounds)
Reactions: NO Adverse Event
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Rituximab 375 MG / M2 Genentech
Dosage: 810-840 mg 5 doses iv
Start date: 2011-05-23
End date: 2011-08-22
Zevalin
Dosage: 31.5 mci once iv
Indication: Lymphoma
Start date: 2011-11-16
Possible Zevalin side effects in
Reported by a consumer/non-health professional from United States on 2012-04-24
Patient:
Reactions: White Blood Cell Count Decreased, Diarrhoea, Hypophagia, Febrile Neutropenia, Perirectal Abscess, Rash Macular
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Metronidazole
Dosage: unk, unknown
Zevalin
Dosage: 4.6 mci, single
Start date: 2011-05-03
End date: 2011-05-03
Metronidazole
Dosage: 500 mg, tid
Administration route: Oral
Indication: Pyrexia
Start date: 2011-06-04
End date: 2011-06-05
Zevalin
Dosage: 31.6 mci, single
Indication: Multiple Myeloma
Start date: 2011-05-12
End date: 2011-05-12
Meropenem
Dosage: 1 g, qd
Indication: Pyrexia
Start date: 2011-06-06
End date: 2011-06-18
Rituxan
Dosage: 200 mg, single
Indication: Multiple Myeloma
Start date: 2011-05-03
End date: 2011-05-03
Rituxan
Dosage: 200 mg, single
Start date: 2011-05-12
End date: 2011-05-12
Cefepime
Dosage: 2 g, tid
Indication: Pyrexia
Start date: 2011-06-03
End date: 2011-06-06
Other drugs received by patient: Atenolol; Neupogen; Fentanyl; Allopurinol; Colchicine; Aspirin; Famvir / 01226201 /; Seroquel; Dilaudid; Vancomycin; Neurontin; Vancomycin; Aztreonam; Ciprofloxacin; Ativan
Possible Zevalin side effects in 55 year old male
Reported by a physician from United States on 2012-04-24
Patient: 55 year old male, weighing 92.0 kg (202.4 pounds)
Reactions: White Blood Cell Count Decreased, Febrile Neutropenia, Toxicity To Various Agents, Perirectal Abscess, Rash Macular, Haemoglobin Decreased, Stem Cell Transplant, Haematocrit Decreased, Catheter Site Erythema, Diarrhoea, Hypophagia, Catheter Site Related Reaction
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Zevalin
Dosage: 4.6 mci, single, intravenous (not otherwise specified)
Indication: Multiple Myeloma
Start date: 2011-05-03
End date: 2011-05-03
Cefepime
Dosage: 2 g, tid, intravenous (not otherwise specified)
Indication: Pyrexia
Start date: 2011-06-03
End date: 2011-06-06
Rituxan
Dosage: 200 mg, single
Indication: Multiple Myeloma
Start date: 2011-05-12
End date: 2011-05-12
Meropenem
Dosage: 1 g, qd, intravenous (not otherwise specified)
Indication: Pyrexia
Start date: 2011-06-06
End date: 2011-06-18
Metronidazole
Dosage: 500 mg, tid, oral
Administration route: Oral
Indication: Prophylaxis
Start date: 2011-06-04
End date: 2011-06-05
Other drugs received by patient: (Famvir / 01226201 / ); Ativan; Allopurinol; Colchicine; Neurontin; Dilaudid; Seroquel; Aspirin; Fentanyl Citrate; Atenolol
Possible Zevalin side effects in
Reported by a consumer/non-health professional from Germany on 2012-04-20
Patient:
Reactions: Delayed Engraftment, Cytomegalovirus Viraemia, Hepatic Failure
Adverse event resulted in: death
Drug(s) suspected as cause:
Rituximab
Dosage: 250 mg/m2, single, on day -22
Indication: Multiple Myeloma
Autologous Stem Cell Transplant
Dosage: at least 2 x 10(6) cd34/kg stem cells, on day 0
Indication: Multiple Myeloma
Rituximab
Dosage: 250 mg/m2, single, on day -14
Indication: Surgical Preconditioning
Zevalin
Dosage: unk, on day -22
Indication: Multiple Myeloma
Melphalan Hydrochloride
Indication: Multiple Myeloma
Zevalin
Dosage: 16 gy, single, on day -14
Indication: Surgical Preconditioning
Melphalan Hydrochloride
Dosage: 100 mg/m2, qd, on days -2 and -1
Indication: Surgical Preconditioning
Other drugs received by patient: Sargramostim
Possible Zevalin side effects in 79 year old male
Reported by a physician from Japan on 2012-04-20
Patient: 79 year old male, weighing 66.0 kg (145.2 pounds)
Reactions: Blood Urea Increased, C-Reactive Protein Increased, Pancytopenia, Mantle Cell Lymphoma Recurrent
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Zevalin
Dosage: 974 mbq, single, intravenous, 130 mbq, single, intravenous
Indication: Mantle Cell Lymphoma Stage I
Start date: 2009-01-27
End date: 2009-01-27
Zevalin
Rituxan
Dosage: unk, unk
Indication: Mantle Cell Lymphoma Stage I
Start date: 2009-01-27
End date: 2009-01-27
Rituxan
Dosage: unk, unk
Indication: Mantle Cell Lymphoma Stage I
Start date: 2009-01-20
End date: 2009-01-20
Other drugs received by patient: Allegra (Fexofenadine) Tablet; Coniel (Benidipine Hydrochloride) Tablet; Other Analgesics and Antipyretics (Other Analgesics and Antipyretics); Doxazosin Mesylate; Urinorm (Benzbromarone) Tablet; Antihistamines (Antihistamines); Valtrex; Maglax (Magnesium Oxide) Tablet
Possible Zevalin side effects in
Reported by a physician from Germany on 2012-04-20
Patient:
Reactions: Gastrointestinal Necrosis
Adverse event resulted in: death
Drug(s) suspected as cause:
Melphalan Hydrochloride
Dosage: 100 mg/m2, qd, on days -2 and -1
Indication: Surgical Preconditioning
Rituximab
Dosage: 250 mg/m2, single, on day -22
Indication: Multiple Myeloma
Rituximab
Dosage: 250 mg/m2, single, on day -14
Indication: Surgical Preconditioning
Melphalan Hydrochloride
Indication: Multiple Myeloma
Autologous Stem Cell Transplant
Dosage: at least 2 x 10(6) cd34/kg stem cells, on day 0
Indication: Multiple Myeloma
Zevalin
Dosage: 20 gy, single, on day -14
Indication: Surgical Preconditioning
Zevalin
Dosage: unk, on day -22
Indication: Multiple Myeloma
Other drugs received by patient: Leukine
Possible Zevalin side effects in
Reported by a physician from Germany on 2012-04-20
Patient:
Reactions: Venoocclusive Disease
Adverse event resulted in: death
Drug(s) suspected as cause:
Melphalan Hydrochloride
Indication: Multiple Myeloma
Rituximab
Dosage: 250 mg/m2, single, on day -14
Indication: Surgical Preconditioning
Melphalan Hydrochloride
Dosage: 100 mg/m2, qd, on days -2 and -1
Indication: Surgical Preconditioning
Zevalin
Dosage: 20 gy, single, on day -14
Indication: Surgical Preconditioning
Rituximab
Dosage: 250 mg/m2, single, on day -22
Indication: Multiple Myeloma
Autologous Stem Cell Transplant
Dosage: at least 2 x 10(6) cd34/kg stem cells, on day 0
Indication: Multiple Myeloma
Zevalin
Dosage: unk, on day -22
Indication: Multiple Myeloma
Other drugs received by patient: Leukine
Possible Zevalin side effects in male
Reported by a consumer/non-health professional from United States on 2012-04-19
Patient: male, weighing 92.0 kg (202.4 pounds)
Reactions: Injection Site Erythema, Diarrhoea, Hypophagia, Febrile Neutropenia, Injection Site Warmth, Perirectal Abscess, Rash Macular
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Metronidazole
Dosage: 500 mg, tid
Administration route: Oral
Indication: Prophylaxis
Start date: 2011-06-04
End date: 2011-06-05
Meropenem
Dosage: 1 g, qd
Indication: Pyrexia
Start date: 2011-06-06
End date: 2011-06-18
Rituxan
Dosage: 200 mg, once/single
Indication: Multiple Myeloma
Start date: 2011-05-12
End date: 2011-05-12
Cefepime
Dosage: 2 g, tid
Indication: Pyrexia
Start date: 2011-06-03
End date: 2011-06-06
Zevalin
Dosage: 31.6 mci, once/single
Indication: Multiple Myeloma
Start date: 2011-05-12
End date: 2011-05-12
Zevalin
Dosage: 4.6 mci, once/single
Start date: 2011-05-03
End date: 2011-05-03
Rituxan
Dosage: 200 mg, once/single
Start date: 2011-05-03
End date: 2011-05-03
Other drugs received by patient: Seroquel; Colchicine; Neurontin; Neupogen; Famvir; Vancomycin; Micafungin; Aspirin; Melphalan Hydrochloride; Dilaudid; Fentanyl; Atenolol; Vancomycin; Allopurinol; Ativan
Possible Zevalin side effects in male
Reported by a consumer/non-health professional from United States on 2012-04-11
Patient: male, weighing 104.3 kg (229.5 pounds)
Reactions: Pneumonia, Fatigue, Nausea, Mental Status Changes, Pyrexia, Asthenia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Rituximab
Dosage: 810-840 mg 5 doses iv
Start date: 2011-05-23
End date: 2011-08-22
Zevalin
Dosage: 31.5 mci once iv
Indication: Lymphoma
Start date: 2011-11-16
Possible Zevalin side effects in 55 year old male
Reported by a physician from Japan on 2012-03-23
Patient: 55 year old male, weighing 65.2 kg (143.4 pounds)
Reactions: Extranodal Marginal Zone B-Cell Lymphoma (Malt Type) Recurrent, Adenovirus Infection, Cystitis Haemorrhagic
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Rituximab (Rituximab)
Dosage: 250 mg/m2, single, iv drip, 250 mg/m2, single, iv drip
Indication: Extranodal Marginal Zone B-Cell Lymphoma (Malt Type) Stage III
Start date: 2009-08-19
End date: 2009-08-19
Rituximab (Rituximab)
Dosage: 250 mg/m2, single, iv drip, 250 mg/m2, single, iv drip
Indication: Extranodal Marginal Zone B-Cell Lymphoma (Malt Type) Stage III
Start date: 2009-08-26
End date: 2009-08-26
Zevalin
Dosage: 130 mbq, single, intravenous
Indication: Extranodal Marginal Zone B-Cell Lymphoma (Malt Type) Stage III
Start date: 2009-08-19
End date: 2009-08-19
Zevalin
Dosage: 965 mbq, single, intravenous;
Indication: Extranodal Marginal Zone B-Cell Lymphoma (Malt Type) Stage III
Start date: 2009-08-26
End date: 2009-08-26
Fludara
Dosage: intravenous
Indication: Extranodal Marginal Zone B-Cell Lymphoma (Malt Type) Stage III
Start date: 2009-03-26
End date: 2009-06-05
Other drugs received by patient: Other Analgesics and Antipyretics (Other Analgesics and Antipyrectics); Antihistamines; Other Analgesics and Antipyretics (Other Analgesics and Antipyrectics); Antihistamines
Possible Zevalin side effects in
Reported by a health professional (non-physician/pharmacist) from United States on 2012-03-14
Patient:
Reactions: Blood Lactate Dehydrogenase Increased, Anaemia, Leukaemoid Reaction, Post Herpetic Neuralgia, Mental Status Changes, Anaemia Macrocytic, Chronic Myeloid Leukaemia, Superinfection Viral, Herpes Zoster, Hypokalaemia, Glycosylated Haemoglobin Increased, Rash Erythematous, Chest Pain, Platelet Count Decreased, Leukocytosis, Blood Glucose Increased
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Rituximab
Dosage: 480 mg, single
Indication: B-Cell Lymphoma
Start date: 2011-03-17
End date: 2011-03-17
Zevalin
Dosage: 6.1 mci, single
Start date: 2011-03-09
End date: 2011-03-09
Rituximab
Dosage: 480 mg, single
Start date: 2011-03-09
End date: 2011-03-09
Zevalin
Dosage: 32 mci, single
Indication: B-Cell Lymphoma
Start date: 2011-03-17
End date: 2011-03-17
Bendamustine
Dosage: 168 to 175 mg, unk
Start date: 2010-10-21
End date: 2010-10-21
Rituximab
Dosage: unk
Start date: 2010-11-23
End date: 2010-11-23
Rituximab
Dosage: unk
Start date: 2010-10-21
End date: 2010-10-21
Bendamustine
Dosage: 168 to 175 mg, unk
Start date: 2010-12-23
End date: 2010-12-23
Bendamustine
Dosage: 168 to 175 mg, unk
Start date: 2010-11-23
End date: 2010-11-23
Rituximab
Dosage: unk
Start date: 2011-01-20
End date: 2011-01-20
Rituximab
Dosage: unk
Start date: 2010-12-23
End date: 2010-12-23
Bendamustine
Dosage: 168 to 175 mg, unk
Indication: B-Cell Lymphoma
Start date: 2011-01-20
End date: 2011-01-20
Other drugs received by patient: Colace; Zoloft; Metaglip; Vicodin; Glucotrol; Mobic; Glucophage; Novolog; Januvia; Aricept
Possible Zevalin side effects in 42 year old female
Reported by a consumer/non-health professional from United States on 2012-03-09
Patient: 42 year old female, weighing 140.0 kg (308.0 pounds)
Reactions: Aplastic Anaemia, Pancytopenia, Febrile Neutropenia, Emotional Disorder
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Zevalin
Dosage: 1df=0.4mcl/kg also 5.8mcl (17aug11-24aug2011).
Indication: Lymphoma
Start date: 2011-08-17
End date: 2011-08-24
Abilify
Dosage: also 2mg
Administration route: Oral
Rituximab
Dosage: 24aug11-24aug11 17aug11:500mg/m2 8jul11:750mg/m2 apr11-unk:375mg/m2
Indication: Lymphoma
Start date: 2011-08-17
End date: 2011-08-24
Other drugs received by patient: Zyrtec; Vitamin B6; Trileptal; Acetaminophen; Calcium; Zoloft; Fish OIL; Vitamin D; Diphenhydramine HCL; Trazodone HCL; Coumadin; Multi-Vitamin
Possible Zevalin side effects in 36 year old female
Reported by a individual with unspecified qualification from Korea, Republic of on 2012-03-08
Patient: 36 year old female
Reactions: Multi-Organ Failure, Interstitial Lung Disease, Acute Respiratory Distress Syndrome
Adverse event resulted in: death, hospitalization
Drug(s) suspected as cause:
Rituximab
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2005-10-01
End date: 2005-10-01
Zevalin
Dosage: 0.4 mci/kg
Indication: Diffuse Large B-Cell Lymphoma
Start date: 2005-10-01
End date: 2005-10-01
Possible Zevalin side effects in female
Reported by a consumer/non-health professional from United States on 2012-03-02
Patient: female, weighing 80.6 kg (177.3 pounds)
Reactions: Blood Lactate Dehydrogenase Increased, Leukocytosis, Herpes Zoster, Chronic Myeloid Leukaemia
Drug(s) suspected as cause:
Zevalin
Dosage: 32 mci once iv
Start date: 2011-03-17
Bendamustine 90 MG / M2 Cephalon
Dosage: 168-175 mg 2 days per cycle iv
Indication: B-Cell Lymphoma
Start date: 2010-10-28
End date: 2011-01-21
Possible Zevalin side effects in
Reported by a health professional (non-physician/pharmacist) from United States on 2012-02-29
Patient:
Reactions: Blood Lactate Dehydrogenase Increased, Anaemia, Post Herpetic Neuralgia, Leukaemoid Reaction, Mental Status Changes, Anaemia Macrocytic, Chronic Myeloid Leukaemia, Herpes Zoster, Superinfection Viral, Hypokalaemia, Glycosylated Haemoglobin Increased, Rash Erythematous, Chest Pain, Platelet Count Decreased, Leukocytosis, Blood Glucose Increased
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Zevalin
Dosage: 32 mci, single
Indication: B-Cell Lymphoma
Start date: 2011-03-17
End date: 2011-03-17
Rituximab
Dosage: 480 mg, single
Start date: 2011-03-09
End date: 2011-03-09
Bendamustine
Dosage: 168 to 175 mg, unk
Start date: 2010-12-23
End date: 2010-12-23
Bendamustine
Dosage: 168 to 175 mg, unk
Start date: 2010-11-23
End date: 2010-11-23
Rituximab
Dosage: unk
Start date: 2010-12-23
End date: 2010-12-23
Bendamustine
Dosage: 168 to 175 mg, unk
Start date: 2010-10-21
End date: 2010-10-21
Zevalin
Dosage: 6.1 mci, single
Start date: 2011-03-09
End date: 2011-03-09
Rituximab
Dosage: unk
Start date: 2011-01-20
End date: 2011-01-20
Rituximab
Dosage: unk
Start date: 2010-11-23
End date: 2010-11-23
Bendamustine
Dosage: 168 to 175 mg, unk
Indication: B-Cell Lymphoma
Start date: 2011-01-20
End date: 2011-01-20
Rituximab
Dosage: 480 mg, single
Indication: B-Cell Lymphoma
Start date: 2011-03-17
End date: 2011-03-17
Rituximab
Dosage: unk
Start date: 2010-10-21
End date: 2010-10-21
Other drugs received by patient: Colace; Glucophage; Metaglip; Mobic; Vicodin; Novolog; Zoloft; Januvia; Aricept; Glucotrol
|